May 11, 2021 By sarahjibrin HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody
Apr 12, 2021 By sarahjibrin Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody
Apr 12, 2021 By sarahjibrin HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers
Apr 12, 2021 By sarahjibrin Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer
Apr 12, 2021 By sarahjibrin Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas
Apr 6, 2021 By sarahjibrin HiFiBiO Therapeutics to Present Progress on Four Novel Immunotherapy Programs at AACR 2021
Mar 19, 2021 By sarahjibrin HiFiBiO and Gustave Roussy Researchers Demonstrate the Contribution of Galectin-9 (Gal-9) in Tumor Immune Escape
Sep 17, 2020 By sarahjibrin HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS® Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference
Jul 3, 2020 By sarahjibrin HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment
Jul 3, 2020 By sarahjibrin Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment
